PRESS Releases


Each year over 80,000 women are diagnosed with gynecologic cancers in the U.S.  There exists an unmet need in the gynecologic cancer market for innovative and accurate molecular biomarker testing that will aid the gynecologic oncologist in personalizing each patient's treatment plan.  OvaGene, through existing tests and future proprietary tests, is poised to fulfill that need with an exciting pipeline of unique gene-based, genomic, and pharmacogenomics tests.

For more information on our company and available investment opportunities, please contact:

Jay Coonan